• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Analyst upgrades Boston Scientific

Analyst upgrades Boston Scientific

August 18, 2009 By MassDevice staff

Boston Scientific Corp. got a boost from Leerink Swann analyst Rick Wise, who upgraded his rating for the Natick, Mass.-based medical devices giant to “outperform.”

“We believe CEO Ray Elliott’s fresh look at the business and relentless focus on driving profitable sales growth will yield significant operating margin expansion and above-average [earnings per share] and cash flow growth,” Wise wrote in a note to investors. “BSX already has made substantial progress towards resolving past challenges, including: 1) reducing debt, 2) stabilizing and even slightly expanding [drug-eluting stent] and [cardiac rhythm management] market share, and 3) completing important steps to resolve its FDA corporate warning letter. With Elliott at the helm, BSX’s progress should accelerate. By 2012, we believe BSX can be a much more prof itable company than today and possibly more profitable than currently reflected in [Wall] Street projections.”

Calling Elliott, who took over at the end of Jim Tobin’s controversial, 10-year reign, a “proven winner,” Wise cited the former Zimmer Holdings CEO’s “long and successful track record.” At Zimmer, Elliott worked closely with Sam Leno, now BoSci’s CFO, and “engineered a major turnaround at [Zimmer] via product innovation, sales force expansion, and relentless focus on consistent execution,” Wise wrote.

“At BSX, we expect more of the same,” he wrote. “Elliott seems set to dial-up the pace of positive change at BSX and already has a number of concrete plans to accelerate product innovation, cost reduction, margin expansion, and cash flow generation — all with a ‘flawless execution’ mindset.”

Predicting an earnings-per-share compound annual growth rate of about 23 percent from 2009 to 2012, Wise wrote that the challenges facing Boston Scientific “seem manageable,” provided it engineers a smooth transition from the Promus stent to the Promus Element stent outside of the United States. And even the roughly $3.75 billion debt payment that comes due during the first half of 2011 is manageable, Wise wrote, if BSC can re-finance and generate enough cash internally.

The Promus line, which is a private-label version of the Xience stent made by Abbott Labs, is sold by Boston Scientific under an agreement it inherited in its 2006 buyout of Guidance Corp.

Filed Under: Business/Financial News, Drug-Eluting Stents

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy